NCT07476118

A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity

A Phase 1b, Randomized, Investigator- and Participant-Blinded, Placebo-Controlled Multiple-Dose Study to Evaluate the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Brenipatide in Healthy Participants With Overweight or Obesity

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 150 (estimated)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to evaluate how different dose levels of brenipatide work and how safe they are in healthy people with overweight or obesity. The study will assess the effects of different doses given as subcutaneous (under the skin) injections. Participation in this study will last about 42 weeks.

Conditions

• Obesity
• Overweight

Interventions

Type	Name	Description
DRUG	Brenipatide	Administered SC.
OTHER	Placebo	Administered SC.

Timeline

• Start date: 2026-03-01
• Primary completion: 2027-02-01
• Completion: 2027-02-01
• First posted: 2026-03-17
• Last updated: 2026-03-17

Locations

3 sites across 1 country: United States

Regulatory

• FDA-regulated drug study